Swisscanto Private Equity

ANYbotics AG is a Swiss robotics company founded in 2016 and based in Zurich. The company specializes in developing autonomous legged robots designed for industrial applications, particularly in hazardous and complex environments. These robots feature advanced capabilities such as docking stations, robust waterproof designs, and various sensing technologies. They are equipped to perform tasks like asset monitoring, equipment health checks, and event detection, thereby enhancing productivity and safety for workers in sectors such as oil and gas, power, energy, mining, chemicals, transportation, and construction. With a team of over 100 employees, ANYbotics aims to support industrial facilities in their inspection needs, promoting more sustainable operations through intelligent robotic solutions.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes microscopic worms for substance testing in pharmaceutical, chemical, and cosmetic industries. Their flagship product, the Caenorhabditis elegans-on-chip, integrates the use of these organisms for in vivo testing with a fully automated platform for in vitro culture, treatment, and analysis. This technology facilitates comprehensive toxicity testing, drug discovery, and anthelmintic testing applications, allowing clients to evaluate biological responses observable only at the whole-organism level. Nagi Bioscience aims to transform traditional testing methodologies by introducing its unique "Organism-on-Chip" technology.

ANYbotics AG is a Swiss robotics company founded in 2016 and based in Zurich. The company specializes in developing autonomous legged robots designed for industrial applications, particularly in hazardous and complex environments. These robots feature advanced capabilities such as docking stations, robust waterproof designs, and various sensing technologies. They are equipped to perform tasks like asset monitoring, equipment health checks, and event detection, thereby enhancing productivity and safety for workers in sectors such as oil and gas, power, energy, mining, chemicals, transportation, and construction. With a team of over 100 employees, ANYbotics aims to support industrial facilities in their inspection needs, promoting more sustainable operations through intelligent robotic solutions.

EcoRobotix Ltd is a Swiss company that specializes in the development and manufacture of autonomous farming machines designed for efficient weeding of row crops, meadows, and intercropping cultures. Founded in 2011 and based in Yverdon-les-Bains, the company offers an innovative product known as ARA, which employs advanced AI for plant recognition and ultra-high precision spraying. This technology allows the machine to detect weeds and apply a micro dose of herbicide directly to them, significantly reducing chemical usage by 70-95%. By utilizing a combination of camera systems, GPS RTK, and sensors, EcoRobotix enables farmers to minimize their environmental impact while lowering operational costs and enhancing crop yields.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Sulzer Schmid is an independent Swiss technology company specializing in advanced solutions for the inspection and analysis of rotor blades. The company has developed a cloud-based platform that provides comprehensive inspection tools and data analytics. This platform offers a transparent view of the health status of rotor blades, enabling windmill operators to capture visual data, process images, and generate customizable reports. By tracking damage progression over time, Sulzer Schmid helps customers make informed decisions regarding repairs and maintenance, ultimately enhancing the efficiency and safety of wind energy operations.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, the company is dedicated to addressing the unmet medical needs of patients globally. Its lead candidate, VS-01, is in the preclinical stage and aims to be the first drug for acute liver disease, with the unique capability of supporting multiple organ function. VS-01 has received Orphan Drug Designation for acute liver failure, highlighting its potential in treating rare conditions. Additionally, Versantis is advancing other products in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent significant opportunities for improving patient outcomes in the field of liver health and beyond.

SWISSto12 SA is a manufacturer of radio frequency (RF) and microwave components and systems, specializing in the production of various antenna types, including horn antennas, airborne Ku and Ka band antenna arrays, and slotted waveguide antennas. The company also offers polymer and metal waveguide products, along with a range of filter products, including diplexers and custom filters. Founded in 2011 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, SWISSto12 utilizes innovative 3D printing techniques to create metal-coated components for (sub)mm-wave signal transmission, enhancing design flexibility while reducing costs and lead times. In addition to its manufacturing capabilities, the company provides integration and testing services, as well as a software solution for material properties extraction. SWISSto12 serves various sectors, including satellite communications, airborne satellites, and research centers, and has operations in Renens, Switzerland, as well as offices in Santa Clara, California, and Rehovot, Israel.